A preventive cardiology case demonstrates how advanced imaging, aggressive lipid optimization, and integrative therapies can reduce coronary plaque burden i ...
Total net revenue of $15.2 million Adjusted EBITDA1 of $ (0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) ...
Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA (gepirone) extended-r ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results